Targeted treatment after surgery for bile duct and gallbladder cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether giving a targeted medicine based on your tumor's genetic makeup, after surgery, can help prevent your bile duct or gallbladder cancer from coming back. It's a new approach that tries to match treatment to your specific cancer biology.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had surgery to remove your bile duct or gallbladder cancer, and the surgeon cleared all visible tumor (or only microscopic cancer cells remain). The cancer must be completely removed (R0 or R1 margin).
- Your cancer is a type called cholangiocarcinoma (bile duct cancer) or gallbladder cancer.
- You are 18 years or older.
- A genetic test of your tumor shows a specific 'targetable' change (molecular alteration) that matches one of the trial's study drugs.
- You have no current evidence of cancer spread (no measurable disease on CT or MRI scans).
- You have not had chemotherapy or radiation for this cancer before (except possibly just after surgery).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination given before surgery to shrink bile duct cancer tumors, potentially making surgery more successful. It is for patients whose cancer is locally advanced or has spread to only a few places.
This trial tests a new drug called mitazalimab, which helps the immune system fight cancer, combined with standard chemotherapy (FOLFOX) for people whose bile duct or gallbladder cancer did not respond to or stopped responding to initial immunotherapy. The goal is to see if this combination can shrink tumors or slow cancer growth better than chemotherapy alone.
This trial tests a combination of two drugs, sacituzumab tirumotecan and pembrolizumab, for people with advanced bile duct or gallbladder cancer that has grown after previous treatment. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests a combination of drugs given before surgery to shrink bile duct cancer and possibly improve outcomes. The drugs include an immunotherapy (tislelizumab) and three chemotherapy agents (gemcitabine, cisplatin, and S-1).
This Phase 3 trial matches people with advanced bile duct cancer or gallbladder cancer to a specific targeted medicine based on their tumor’s lab results. It aims to improve disease control by using the right drug for the specific changes found in the cancer.
This trial tests a new targeted therapy, futibatinib, for people with advanced or unresectable bile duct cancer who have not had prior treatment for advanced disease. It aims to see if this drug can help shrink or control the cancer.
Hear when a new Biliary Tract Cancer (BTC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.